Epoch Investment Partners Inc. Has $52.26 Million Holdings in Pfizer Inc. (NYSE:PFE)

Epoch Investment Partners Inc. cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.1% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 1,867,744 shares of the biopharmaceutical company’s stock after selling 40,732 shares during the period. Epoch Investment Partners Inc.’s holdings in Pfizer were worth $52,259,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of PFE. 1832 Asset Management L.P. boosted its holdings in shares of Pfizer by 24,961.6% in the 2nd quarter. 1832 Asset Management L.P. now owns 2,497,886 shares of the biopharmaceutical company’s stock valued at $69,891,000 after buying an additional 2,487,919 shares during the last quarter. Frank Rimerman Advisors LLC raised its holdings in shares of Pfizer by 32,348.1% in the 2nd quarter. Frank Rimerman Advisors LLC now owns 101,887 shares of the biopharmaceutical company’s stock valued at $2,851,000 after purchasing an additional 101,573 shares during the period. ProShare Advisors LLC increased its position in Pfizer by 7.3% during the second quarter. ProShare Advisors LLC now owns 845,638 shares of the biopharmaceutical company’s stock worth $23,661,000 after buying an additional 57,825 shares during the last quarter. Kowal Investment Group LLC lifted its position in shares of Pfizer by 10.3% in the second quarter. Kowal Investment Group LLC now owns 18,834 shares of the biopharmaceutical company’s stock valued at $527,000 after buying an additional 1,757 shares during the last quarter. Finally, Schwerin Boyle Capital Management Inc. increased its holdings in shares of Pfizer by 8.2% during the 2nd quarter. Schwerin Boyle Capital Management Inc. now owns 775,125 shares of the biopharmaceutical company’s stock worth $21,688,000 after acquiring an additional 58,850 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the topic of several research reports. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Barclays increased their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Wells Fargo & Company boosted their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, UBS Group increased their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Price Performance

PFE stock opened at $29.42 on Monday. The company’s 50-day moving average price is $29.36 and its two-hundred day moving average price is $28.24. The firm has a market cap of $166.71 billion, a P/E ratio of -490.25, a P/E/G ratio of 1.05 and a beta of 0.68. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $34.11.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same period last year, the firm posted $0.67 earnings per share. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were issued a dividend of $0.42 per share. The ex-dividend date was Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.71%. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.